A new $15 million initiative between Pfizer and the American Cancer Society (ACS) aims to tackle one of the most pressing issues in health at the moment – unequal access t
The detrimental issues within health systems in developing countries have become intrinsic to their model, with lack of funding and resources, as well as systemic issues, causing inequality
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh